Pfizer Inc.

New York, NY Doing business as Pfizer

UEI
MHBQULRMEEJ5
CAGE
86491
Primary NAICS
325412 Pharmaceutical Preparation Manufacturing
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Manufacturer of Goods
Entity structure
Corporate Entity (Not Tax Exempt)
NAICS codes registered in SAM.gov
Corporate family
SAM.gov registration date
Physical address
66 Hudson Blvd E, New York, NY 10001, USA
Website
pfizer.com
Founded
1849
Employees
50K-100K
Estimated annual revenue
$10B+
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Recent federal awards

Pfizer Inc.'s 5 most recent federal contract and grant awards, newest first. Amounts are dollars obligated.
Award Agency Obligated Awarded
4571942076 ! Sodium chloride 0.9% vial 10ML Contract · SPE2D326F150C Medical Supply Chain $37
4571942325 ! Premarin 25 MG vials Contract · SPE2D326F150J Medical Supply Chain $1,124
4571942326 ! Cyklokapron 1,000 MG/10 ML VL 10ML Contract · SPE2D326F150H Medical Supply Chain $180
4571942077 ! Ondansetron HCL 4 MG/2 ML vial 2ML Contract · SPE2D326F149Y Medical Supply Chain $11
4571934403 ! Ceftriaxone 1 GM vials Contract · SPE2D326F149C Medical Supply Chain $96

About Pfizer Inc.

Written by GovTribe AI ·

Pfizer Inc., doing business as Pfizer, is a for-profit pharmaceutical manufacturer headquartered in New York, New York, that supplies pharmaceutical products, vaccines, and biologics to the federal government as a prime contractor on a full-and-open (non-set-aside) basis. Pfizer competes across 35 distinct federal agencies with a portfolio of 6,332 prime awards totaling $98.9 billion in combined potential value, of which $45.1 billion has been obligated. The company operates through multiple subsidiaries including Array BioPharma, King Pharmaceuticals, Meridian Medical Technologies, Hospira Worldwide, Wyeth Consumer Healthcare, and Greenstone, which collectively expand its product and delivery footprint across pharmaceutical manufacturing and biologics.

Pfizer's federal customer base concentrates heavily in defense and health services procurement. The Defense Logistics Agency's Troop Support Medical Supply Chain accounts for 5,229 awards (83% of volume by count) with $223.6 million in combined potential value, representing the dominant order-flow customer. By potential-value magnitude, concentration shifts: the Centers for Disease Control and Prevention Pittsburgh leads with $26.58 billion across 42 awards, followed by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 12 with $21.81 billion across 35 awards, and the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response with $9.41 billion across 15 awards. These three customers alone account for 59% of Pfizer's combined federal potential value. The contrast between volume concentration (DLA at 83% of award count) and dollar concentration (CDC at 27% of potential value) reflects Pfizer's dual role: high-volume spot buys of low-cost injectables and surgical supplies through DLA's Medical Supply Chain, paired with large-ceiling indefinite delivery contracts for vaccines and specialized biologics through CDC and VA health systems.

Pfizer holds positions on multiple prime vehicles anchoring its federal business. The primary vehicle is an Indefinite Delivery Contract (SPE2D020D0014) with 4,387 task orders valued at $6.9 million in combined potential value; this appears to be DLA's core mechanism for ordering pharmaceutical supplies. A second IDC (SPM2D012D0022) carries 768 task orders worth $4.5 million. Pfizer also maintains GSA Federal Supply Schedules (V797P5883X with 428 task orders valued at $7.7 million; V797P5547M with 138 task orders). Recent high-value awards include a $112.8 million multiple-award IDC from CDC Pittsburgh for adult vaccines (Hepatitis A and B, HPV, herpes zoster, meningococcal, MMR, pneumococcal, Tdap, varicella, RSV, MPOX, and enhanced IPV vaccines) effective July 1, 2026 through June 30, 2027, and a $735.7 million multiple-award IDC from CDC Pittsburgh for pediatric COVID-19 vaccines under the Vaccine for Children program running June 1, 2026 through May 31, 2027. A third vehicle, a BPA call from the Office of the Assistant Secretary for Preparedness and Response, awarded Pfizer $542,604.96 on May 15, 2026, for sterile water for injection in 20 mL vials. Representative delivery-order work from the past two years spans naloxone, fentanyl, Cleocin, lidocaine, ceftriaxone, Solu-Medrol, Silvadene, Premarin, and other branded and generic injectables—most ceiling values under $2,000 per line item, reflecting rapid replenishment ordering of hospital and emergency medical supplies through DLA's Medical Supply Chain.

Activity has declined modestly year over year (867 awards in 2022 to 528 in 2026 year-to-date), but the recompete cliff is minimal: only four awards totaling $4.6 million in combined potential value reach ultimate completion within the next twenty-four months. The imminent CDC vaccines IDCs (both effective July 1, 2026 and June 1, 2026 respectively, with one-year terms) represent the material recompete exposure for Pfizer's federal footprint. Pfizer's capability portfolio concentrates in NAICS 325412 (Pharmaceutical Preparation Manufacturing) for 5,036 awards and 325411 (Medicinal and Botanical Manufacturing) for 858 awards, grounded in product PSCs: 6,036 awards under Drugs and Biologicals, 164 under Medical and Surgical Instruments and Equipment, and smaller volumes of surgical dressing and laboratory supplies. Service Contract Inventory data show minimal SCI-reportable activity—$460 thousand invoiced in FY2022 across 0.1 FTEs—indicating that Pfizer's federal revenue stream is overwhelmingly products and goods procurement rather than labor services, consistent with its manufacturing and supply-chain role.

Contract vehicles

Pfizer Inc. holds a place on 3 federal contract vehicles. Active vehicles first.

Quick answers

What is Pfizer Inc.'s UEI?

Pfizer Inc.'s Unique Entity ID (UEI) in SAM.gov is MHBQULRMEEJ5.

What is Pfizer Inc.'s CAGE code?

Pfizer Inc.'s CAGE code is 86491.

What is Pfizer Inc.'s primary NAICS code?

Pfizer Inc.'s primary NAICS code is 325412 (Pharmaceutical Preparation Manufacturing).

Where is Pfizer Inc. located?

Pfizer Inc.'s physical address in SAM.gov is 66 Hudson Blvd E, New York, NY 10001, USA.

Is Pfizer Inc. registered in SAM.gov?

Yes. Pfizer Inc.'s SAM.gov registration is active through August 5, 2027.

Which contract vehicles does Pfizer Inc. hold?

Pfizer Inc. holds a place on 3 federal contract vehicles, including FSS-61-IB.

What is Pfizer Inc.'s most recent federal award?

Pfizer Inc.'s most recent federal contract award is 4571942076 ! Sodium chloride 0.9% vial 10ML (SPE2D326F150C), from Medical Supply Chain, on May 27, 2026.

On GovTribe

See Pfizer Inc.'s full federal record

  • Federal contract awards
  • IDV awards
  • Contract vehicles
  • Subcontracting relationships
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login